Chris Aaron Lemmon , MD

BS: The Ohio State University Columbus, OH, 2008 (Microbiology)

MD: St. George's University Grenada, West Indies, 2015

Residency: Medical College of Georgia Augusta, GA, 2018 (Internal Medicine Residency)

Fellowship: University of Florida College of Medicine Jacksonville, FL, 2019 (Patient Safety)

Fellowship: Cleveland Clinic Foundation Cleveland, OH, 2022 (Hematology/Medical Oncology)

American Board of Internal Medicine (Certification Date: 08-23-2018 )

American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-29-2022 )

Medical Oncology

Oncology

Head and Neck Cancer

Thoracic Cancer

Internal Medicine

Medical Oncology

Grant: #FLM-6774-201 Investigators:Lemmon, Christopher 01-08-2024 -01-08-2027 Flamingo Therapeutics An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Role:PI 640700.93 Hold Level:Industry

Grant: #AV-299-23-301 Investigators:Lemmon, Chris 02-18-2024 -01-15-2027 Aveo Pharmaceuticals A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck S Role:PI 0.00 Hold Level:Industry

Grant: #GO45006 Investigators:Lemmon, Chris 05-30-2024 -05-30-2027 Genentech, Inc. A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB COMPARED WITH PLACEBO PLUS ATEZOLIZUMAB IN PARTICIPANTS WITH COMPLETELY RESECTED STAGE IIB, IIIA, OR SELECT IIIB, PD-L1 POS Role:PI 1801907.99 Hold Level:Industry

Investigators:Lemmon, Chris 08-23-2024 -08-23-2027 BioNTech SE An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head Role:PI 0.00 Hold Level:Industry

Grant: #MCLA-158-CL02 Investigators:Lemmon, Chris 08-22-2024 -08-22-2027 Merus N.V. A phase III open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with i Role:PI 754006.04 Hold Level:Industry

Grant: #MK-2870-004 Investigators:Lemmon, Chris 08-26-2024 -08-26-2027 Merck Sharp & Dohme LLC A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutat Role:PI 1347124.88 Hold Level:Industry

Grant: #TP-CA-006 Investigators:Lemmon, Chris 09-23-2024 -09-23-2027 Tempus A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC) Role:PI 760470.71 Hold Level:Industry

Grant: #MK-1084-004 Investigators:Lemmon, Chris 10-07-2024 -10-07-2027 Merck Sharp & Dohme LLC A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as First-line Treatment of Participants With KRAS G12C-Muta Role:PI 1834048.28 Hold Level:Industry

Grant: #221530 Investigators:Lemmon, Chris 10-21-2024 -10-21-2027 Glaxo Smith Kline A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Role:PI 0.00 Hold Level:Industry

Peer Reviewed Publications

Lemmon, Christopher A; Videtic, Gregory M M; Murthy, Sudish; Stephans, Kevin L; Shapiro, Marc; Ahmad, Usman; Raymond, Daniel; Velcheti, Vamsidhar; Bribriesco, Alejandro; Jia, Xuefei; Stevenson, James; Pennell, Nathan A (2022. ) A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC.JTO clinical and research reports, , 3 (7 ) ,100359 More Information

Lemmon, Christopher A; Zabor, Emily C; Pennell, Nathan A (2022. ) Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.The oncologist, , 27 (5 ) ,407-413 More Information

, (2020. ) A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.Cancer cell, , 38 (6 ) ,761-766 More Information

Rivera, Donna R; Peters, Solange; Panagiotou, Orestis A; Shah, Dimpy P; Kuderer, Nicole M; Hsu, Chih-Yuan; Rubinstein, Samuel M; Lee, Brendan J; Choueiri, Toni K; de Lima Lopes, Gilberto; Grivas, Petros; Painter, Corrie A; Rini, Brian I; Thompson, Michael A; Arcobello, Jonathan; Bakouny, Ziad; Doroshow, Deborah B; Egan, Pamela C; Farmakiotis, Dimitrios; Fecher, Leslie A; Friese, Christopher R; Galsky, Matthew D; Goel, Sanjay; Gupta, Shilpa; Halfdanarson, Thorvardur R; Halmos, Balazs; Hawley, Jessica E; Khaki, Ali Raza; Lemmon, Christopher A; Mishra, Sanjay; Olszewski, Adam J; Pennell, Nathan A; Puc, Matthew M; Revankar, Sanjay G; Schapira, Lidia; Schmidt, Andrew; Schwartz, Gary K; Shah, Sumit A; Wu, Julie T; Xie, Zhuoer; Yeh, Albert C; Zhu, Huili; Shyr, Yu; Lyman, Gary H; Warner, Jeremy L (2020. ) Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.Cancer discovery, , 10 (10 ) ,1514-1527 More Information

Lemmon, Christopher; Pennell, Nathan A (2020. ) Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?.Journal of thoracic disease, , 12 (9 ) ,5042-5045 More Information

Kuderer, Nicole M; Choueiri, Toni K; Shah, Dimpy P; Shyr, Yu; Rubinstein, Samuel M; Rivera, Donna R; Shete, Sanjay; Hsu, Chih-Yuan; Desai, Aakash; de Lima Lopes, Gilberto; Grivas, Petros; Painter, Corrie A; Peters, Solange; Thompson, Michael A; Bakouny, Ziad; Batist, Gerald; Bekaii-Saab, Tanios; Bilen, Mehmet A; Bouganim, Nathaniel; Larroya, Mateo Bover; Castellano, Daniel; Del Prete, Salvatore A; Doroshow, Deborah B; Egan, Pamela C; Elkrief, Arielle; Farmakiotis, Dimitrios; Flora, Daniel; Galsky, Matthew D; Glover, Michael J; Griffiths, Elizabeth A; Gulati, Anthony P; Gupta, Shilpa; Hafez, Navid; Halfdanarson, Thorvardur R; Hawley, Jessica E; Hsu, Emily; Kasi, Anup; Khaki, Ali R; Lemmon, Christopher A; Lewis, Colleen; Logan, Barbara; Masters, Tyler; McKay, Rana R; Mesa, Ruben A; Morgans, Alicia K; Mulcahy, Mary F; Panagiotou, Orestis A; Peddi, Prakash; Pennell, Nathan A; Reynolds, Kerry; Rosen, Lane R; Rosovsky, Rachel; Salazar, Mary; Schmidt, Andrew; Shah, Sumit A; Shaya, Justin A; Steinharter, John; Stockerl-Goldstein, Keith E; Subbiah, Suki; Vinh, Donald C; Wehbe, Firas H; Weissmann, Lisa B; Wu, Julie Tsu-Yu; Wulff-Burchfield, Elizabeth; Xie, Zhuoer; Yeh, Albert; Yu, Peter P; Zhou, Alice Y; Zubiri, Leyre; Mishra, Sanjay; Lyman, Gary H; Rini, Brian I; Warner, Jeremy L (2020. ) Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.Lancet (London, England), , 395 (10241 ) ,1907-1918 More Information

Lemmon, Christopher A; Zhou, Jie; Hobbs, Brian; Pennell, Nathan A (2023. ) Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.JCO precision oncology, , 7 ,e2200294 More Information

2015-2018 Internal Medicine, Medical College of Georgia, ,

2018-2019 Patient Safety Fellowship, University of Florida COM - Jacksonville, ,

2019-2022 Hematology and Medical Oncology, Cleveland Clinic Foundation, ,